FibroBiologics, Inc. entered into a securities purchase agreement on September 15, 2026, with Hamid Khoja, Ph.D., its Chief Scientific Officer, for a private placement of 298,508 shares of common stock and accompanying warrants to purchase an equal number of shares. The offering price was $1.675 per share and warrant combination, generating approximately $0.5 million in gross proceeds before expenses. The warrants carry a $1.55 exercise price and expire five years from issuance. Proceeds are intended for general corporate purposes and working capital. FibroBiologics operates in the biotechnology industry, focusing on developing therapies for fibrotic diseases.
